07:00 , Oct 17, 2011 |  BC Week In Review  |  Financial News

Amarantus BioSciences completes bridge financing

Amarantus BioSciences Inc. (OTCBB:AMBS), Sunnyvale, Calif.   Business: Neurology, Cardiovascular   Date completed: 10/10/11   Type: Bridge financing   Raised: $150,000   Investor: Atlantic Partners   Note: The convertible bridge loan bears 20% interest and...
08:00 , Mar 3, 2008 |  BioCentury  |  Finance

Ebb & Flow

Ophthalmology company InSite Vision managed to get its non-dilutive financing done last week, but it will pay a pretty penny: the interest rate on the $60 million non-convertible note deal is 16%. Chairman, President and...
07:00 , Oct 10, 2005 |  BioCentury  |  Finance

Ebb & Flow

Having raised money for its shell company via an IPO in August, Ithaka (ITHKU) is now doing what it was designed to do: find a private healthcare company to merge into the shell. ITHKU is...
07:00 , Apr 5, 2004 |  BC Week In Review  |  Company News

Eximias board of directors update

Eximias Pharmaceutical Corp. , Berwyn, Penn.   Business: Cancer   Appointed: John Cassis, partner at Cross Atlantic Partners; Brenda Gavin, managing partner at Quaker BioVentures; Michael Sheffery, general partner at OrbiMed Advisors; and M. James...
07:00 , Apr 5, 2004 |  BioCentury  |  Finance

Ebb & Flow

Private investors continued their love affair with the life sciences, as Alta Partners raised $475 million for two funds last week, and - in a slight change of direction - all of the money will...
08:00 , Mar 31, 2004 |  BC Extra  |  Financial News

Eximias raises $63.5 million

Cancer company Eximias (Berwyn, Penn.) raised $63.5 million in a series D round co-led by Cross Atlantic Partners and Quaker BioVentures. Other investors included New Enterprise Associates; OrbiMed; Birchmere; Easton Hunt Capital; Cross Atlantic Capital;...
07:00 , Oct 6, 2003 |  BioCentury  |  Finance

Ebb & Flow

Those reading ID Biomedical's press release justifying its decision to pull its follow-on on Friday might have asked what happened to the bull market for biotech. Since filing the deal on Sept. 25, IDBE said...
07:00 , May 12, 2003 |  BioCentury  |  Finance

Ebb & Flow

For the past few years, the major focus for investors in Neurobiological Technologies (NTII) has been on its Memantine , which is marketed in Europe for Alzheimer's disease and is awaiting U.S. approval for the...
07:00 , May 9, 2003 |  BC Extra  |  Top Story

Acorda raises $55.3M

Acorda (Hawthorne, N.Y.) raised $55.3 million in a private round led by Easton Hunt Capital Partners. Other investors included ABN AMRO; Cross Atlantic Partners; JPMorgan Fleming Asset Management; TVM Techno Venture Management; Forward Ventures; MDS...
07:00 , Aug 13, 2001 |  BioCentury  |  Finance

Ebb & Flow

Genzyme (GENZ) moved to consolidate its grip in the enzyme replacement space, but wasn't instantly rewarded for its plans to acquire protein engineering play Novazyme for $137.5 million in stock. After pushing GENZ up $0.26...